Zymeworks reports FY 2022 net income $124.3M vs loss; $492.2M cash; Jazz deal $375M upfront

Zymeworks Inc.

Revenue $412.5M (FY22) vs $26.7M (FY21) driven by $375M upfront from Jazz collaboration.
Net income $124.3M ($1.90 diluted EPS) vs net loss $211.8M in prior year; cash $492.2M through 2026.
Jazz deal total potential $1.76B; tiered royalties 10-20% on Jazz net sales if approved.
Zanidatamab: Phase 2 BTC cORR 41.3%, median DOR 12.9 months; GEA 84% OS at 18mo.
2023 net cash burn guidance $90-120M incl. $15M capex; zanidatamab zovodotin Phase 2 studies start 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Zymeworks Inc. reported the fourth quarter and year ended December 31, 2022 results: revenue $412.5 million, net income $124.3 million ($1.90 per fully diluted share), EPS $1.90 per fully diluted share.

Period: the fourth quarter and year ended December 31, 2022
Revenue: $412.5 million
Net income: $124.3 million ($1.90 per fully diluted share)
EPS: $1.90 per fully diluted share
Result: reported results

Exact text from the filing

Zymeworks Reports Fourth Quarter and Full Year 2022 Financial Results • 2022 was a year of transformation and change: ◦ reported $412.5 million in total revenue for the year ended December 31, 2022; ◦ reported net income of $124.3 million ($1.90 per fully diluted share) for 2022 compared to net loss of $211.8 million in 2021;

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

Zymeworks Inc. filing history →

Source: SEC EDGAR

accession 0001937653-23-000008

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.